Correlation of MR-Based Metabolomics and Molecular Profiling in the Tumor Microenvironment of Temozolomide-Treated Orthotopic GL261 Glioblastoma in Mice

Autor: Kai Zhao, Pilar Calero-Pérez, Miriam H. A. Bopp, Vincent Möschl, Axel Pagenstecher, Marta Mulero-Acevedo, Mario Vázquez, Carlos Barcia, Carles Arús, Christopher Nimsky, Tillmann Rusch, Jörg W. Bartsch, Ana Paula Candiota

Publikováno v: International Journal of Molecular Sciences, Vol 24, Iss 24, p 17628 (2023)

The tumor microenvironment in glioblastoma (GB) is considered to be “cold”, i.e., the fraction of cytotoxic T cells, for instance, is low. Instead, macrophages are the major immune cell population in GB, which stem either from tissue response (re

Externí odkaz: https://doaj.org/article/c45c798956f541c28aa98a2d1cd8b57e

Establishing Imaging Biomarkers of Host Immune System Efficacy during Glioblastoma Therapy Response: Challenges, Obstacles and Future Perspectives

Autor: Ana Paula Candiota, Carles Arús

Publikováno v: Metabolites, Vol 12, Iss 3, p 243 (2022)

This hypothesis proposal addresses three major questions: (1) Why do we need imaging biomarkers for assessing the efficacy of immune system participation in glioblastoma therapy response? (2) Why are they not available yet? and (3) How can we produce

Externí odkaz: https://doaj.org/article/52b9663795ca4699b4afc661164fdb6b

Synthesis and Validation of a Bioinspired Catechol-Functionalized Pt(IV) Prodrug for Preclinical Intranasal Glioblastoma Treatment

Autor: Xiaoman Mao, Shuang Wu, Pilar Calero-Pérez, Ana P. Candiota, Paula Alfonso, Jordi Bruna, Victor J. Yuste, Julia Lorenzo, Fernando Novio, Daniel Ruiz-Molina

Publikováno v: Cancers
Cancers, Vol 14, Iss 410, p 410 (2022)
Dipòsit Digital de la UB
Universidad de Barcelona
Cancers; Volume 14; Issue 2; Pages: 410
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona

Glioblastoma is the most malignant and frequently occurring type of brain tumors in adults. Its treatment has been greatly hampered by the difficulty to achieve effective therapeutic concentration in the tumor sites due to its location and the blood�

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea58c599af59a49701951f26d45002f6
https://pubmed.ncbi.nlm.nih.gov/35053575

Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment

Autor: Nuria Arias-Ramos, Laura Ferrer-Font, Silvia Lope-Piedrafita, Victor Mocioiu, Margarida Julià-Sapé, Martí Pumarola, Carles Arús, Ana Paula Candiota

Publikováno v: Metabolites, Vol 7, Iss 2, p 20 (2017)

Glioblastoma (GBM) is the most common aggressive primary brain tumor in adults, with a short survival time even after aggressive therapy. Non-invasive surrogate biomarkers of therapy response may be relevant for improving patient survival. Previous w

Externí odkaz: https://doaj.org/article/5e19de8bad1045ad974b2bedaa66423d

Platinum-Based Nanoformulations for Glioblastoma Treatment: The Resurgence of Platinum Drugs?

Autor: Paula Alfonso-Triguero, Julia Lorenzo, Ana Paula Candiota, Carles Arús, Daniel Ruiz-Molina, Fernando Novio

Publikováno v: Nanomaterials, Vol 13, Iss 10, p 1619 (2023)

Current therapies for treating Glioblastoma (GB), and brain tumours in general, are inefficient and represent numerous challenges. In addition to surgical resection, chemotherapy and radiotherapy are presently used as standards of care. However, trea

Externí odkaz: https://doaj.org/article/6fd0f54afbb346ba9deddff071f55a36